MANGOCEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed herewith or incorporated by reference herein:
| Incorporated by Reference | ||||
|---|---|---|---|---|
| Exhibit Number · Description of Exhibit · Filed/ Furnished Herewith · Form · Exhibit · Filing Date | ||||
| 3.1 | Certificate of Designations, Preferences and Rights of 6% Series B Convertible Preferred Stock of Mango & Peaches Corp., filed with the Secretary of State of Texas on July 3, 2025 | 8-K | 3.1 | 7/9/2025 |
| 4.1 | Form of Common Stock Purchase Warrant – Unit Offering (May 2025) | 8-K | 4.1 | 5/29/2025 |
| 4.2 | Common Stock Purchase Warrant to purchase 275,482 shares of common stock, issued to Indigo Capital LP dated May 27, 2025 | 8-K | 4.2 | 5/29/2025 |
| 4.3# | Common Stock Purchase Warrant to purchase 50,000 shares of common stock, issued to Tiger Cub Trust dated July 21, 2025 | 8-K | 4.1 | 7/22/2025 |
| 10.1 | Master Distribution Agreement dated March 24, 2025, between Navy Wharf, Ltd, as supplier, and Mangoceuticals, Inc., as distributor | 8-K | 10.1 | 3/25/2025 |
| 10.2 | Form of Securities Purchase Agreement dated April 11, 2025, relating to the sale of 100 shares of Series B Convertible Preferred Stock | 8-K | 10.1 | 4/17/2025 |
| 10.3 | Promissory Note dated April 15, 2025, evidencing $500,000 owed by Mangoceuticals, Inc. to Indigo Capital LP | 8-K | 10.2 | 4/17/2025 |
| 10.4+ | Intellectual Property Purchase Agreement dated April 24, 2025, by and between Mangoceuticals, Inc., as purchaser and Smokeless Technology Corp., as seller | 8-K | 10.1 | 4/25/2025 |
| 10.5+ | Consulting Agreement dated April 24, 2025, between Mangoceuticals, Inc. and Strategem Solutions, Inc. | 8-K | 10.2 | 4/25/2025 |
| 10.6# | First Amendment to Amended and Restated Executive Employment Agreement dated April 24, 2025 and effective April 1, 2025, by and between Mangoceuticals, Inc. and Jacob Cohen | 8-K | 10.3 | 4/25/2025 |
| 10.7# | Promissory Note dated May 2, 2025 in the principal amount of $100,000, between Mangoceuticals, Inc., borrower and The Tiger Cub Trust, lender | 8-K | 10.1 | 5/6/2025 |
| 10.8 | Master Distribution Agreement dated May 14, 2025, between PrevenTech Solutions, LLC, as distributor, and Mangoceuticals, Inc., as supplier | 10-Q | 10.23 | 5/15/2025 |
| 10.9 | Mutual Rescission and Release Agreement dated May 22, 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and ArcStone Securities and Investments Corp. | 8-K | 10.1 | 5/23/2025 |
| 10.10 | Mutual Rescission and Release Agreement dated May 22, 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and Smokeless Technology Corp. | 8-K | 10.2 | 5/23/2025 |
| 10.11 | Mutual Rescission and Release Agreement dated May 22 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and Strategem Solutions Inc. | 8-K | 10.3 | 5/23/2025 |
| 10.12 | Form Common Stock Subscription Agreement – Unit Offering (May 2025) | 8-K | 10.1 | 5/29/2025 |
| 10.13 | Agreement to Amend Promissory Note dated May 27, 2025, by and between Mangoceuticals, Inc. and Indigo Capital LP | 8-K | 10.2 | 5/29/2025 |
| 10.14 | Amended and Restated Convertible Promissory Note dated May 27, 2025, by and between Mangoceuticals, Inc., as borrower, and Indigo Capital LP, as holder | 8-K | 10.3 | 5/29/2025 |
| 10.15# | Agreement to Amend Promissory Note dated July 21, 2025, by and between Mangoceuticals, Inc. and to Tiger Cub Trust | 8-K | 10.2 | 7/22/2025 |
| 10.16# | Amended and Restated Convertible Promissory Note dated July 21, 2025, by and between Mangoceuticals, Inc., as borrower, and to Tiger Cub Trust, as holder | 8-K | 10.3 | 7/22/2025 | |
| 10.17 | Mutual Rescission and Release Agreement dated and effective July 30, 2025, by and between Mangoceuticals, Inc. and Navy Wharf, Ltd. | 8-K | 10.1 | 8/4/2025 | |
| 10.18 | Form of Common Stock Subscription Agreement – Common Stock Offering (August 2025 Private Offering) | 8-K | 10.1 | 9/2/2025 | |
| 10.19# | Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Incentive Plan | 8-K | 10.2 | 3/19/2025 | |
| 10.20# | Mangoceuticals, Inc. 2022 Equity Incentive Plan Stock Option Agreement dated September 9, 2025 – Jacob Cohen – 500,000 shares | 8-K | 10.2 | 9/12/2025 | |
| 10.21 | Lease Agreement dated as of October 27, 2025 by and between SVHQ, LLC, as Landlord, and Mangoceuticals, Inc., as Tenant | 8-K | 10.1 | 10/28/2025 | |
| 10.22# | Separation Agreement dated as of October 27, 2025 by and between Mangoceuticals, Inc. and Amanda Hammer | 8-K | 10.2 | 10/28/2025 | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | X | |||
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | X | |||
| 32.1** | Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act | X | |||
| 32.2** | Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act | X | |||
| 101.INS* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | |||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set | X | |||
- Filed herewith.
** Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.